Evidence map›Paper›PMID 37875918›Full record

ArticleJournal of nanobiotechnology2023

Dual antibody-aided mesoporous nanoreactor for H

Ying-Tzu Chen, Ying-Xiang Luo, Shih-Hsuan Chan, Wen-Yi Chiu, Hung-Wei Yang

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Ying-Tzu ChenDepartment of Biomedical Engineering, National Cheng Kung University, Tainan, 70101, Taiwan.
Ying-Xiang LuoInstitute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, 80424, Taiwan.
Shih-Hsuan ChanSchool of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan.
Wen-Yi Chiu *Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, 80424, Taiwan. hanrogyi@gmail.com.
Hung-Wei Yang *Department of Biomedical Engineering, National Cheng Kung University, Tainan, 70101, Taiwan. howardyang@gs.ncku.edu.tw.
National Sun Yat-sen University · TWChang Gung Memorial Hospital · TWChina Medical University · TWNational Cheng Kung University · TW

Funding

National Health Research Institutes NHRI-EX112-11226EINational Science and Technology Council NSTC110-2628-B-110-004; NSTC111-2628-B-006-023; NSTC112-2628-B-006-015
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) represents a formidable challenge due to the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, rendering it unresponsive to conventional hormonal and targeted therapies. This study introduces the development of mesoporous nanoreactors (NRs), specifically mPDA@CuO

Indexed as

Triple Negative Breast NeoplasmsAntibodies, MonoclonalB7-H1 AntigenCopperDiazonium CompoundsHumansHydrogen PeroxideImmune Checkpoint InhibitorsImmunotherapyNanotechnologyPyridines3-(2'-pyridyldithio)benzyldiazoacetateAntibodies, MonoclonalB7-H1 AntigenCoppercupric oxideDiazonium CompoundsHydrogen PeroxideImmune Checkpoint InhibitorsPyridinesCheckpoint blockade immunotherapyChemodynamic therapy (CDT)Collaborative treatmentMesoporous nanoreactorsTriple-negative Breast cancer (TNBC)

Identifiers

PMID37875918
PMCPMC10594761
OpenAlexW4387905288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.